Summit Trail Advisors’s AngioDynamics ANGO Stock Holding History

Summit Trail Advisors’s Portfolio ANGO Stock Details ANGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-8	Closed	–	–	492
2017 Q4	$0	Buy	+8	New	+$137	﹤0.01%	1968

Other funds holding ANGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Summit Trail Advisors's ANGO Position: Q1 2018 in Review

Summit Trail Advisors sold out of AngioDynamics (ANGO) in Q1 2018, closing a stake of 8 shares.

Summit Trail Advisors first reported a position in ANGO in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 164 funds tracked by Wall St. Rank hold ANGO as of Q1 2018.

Summit Trail Advisors reported no remaining AngioDynamics position as of Q1 2018 after selling out during the quarter.
Summit Trail Advisors sold 8 AngioDynamics shares in Q1 2018.
Summit Trail Advisors first reported a position in AngioDynamics in Q4 2017 and held it in 1 quarter.
Summit Trail Advisors's AngioDynamics position peaked at $0 in Q4 2017.
164 funds tracked by Wall St. Rank held AngioDynamics as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.